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Cancer genome sequencing studies have identified numerous driver genes but the relative timing 
of mutations in carcinogenesis remains unclear. The gradual progression from pre-malignant 
Barrett’s esophagus to esophageal adenocarcinoma (EAC) provides an ideal model to study the 
ordering of somatic mutations. We identified recurrently-mutated genes and assessed clonal 
structure using whole-genome sequencing and amplicon-resequencing of 112 EACs. We next 
screened a cohort of 109 biopsies from two key transition points in the development of 
malignancy; benign metaplastic never-dysplastic Barrett’s esophagus (NDBE, n=66), and high-
grade dysplasia (HGD, n=43). Unexpectedly, the majority of recurrently mutated genes in EAC 
were also mutated in NDBE. Only TP53 and SMAD4 were stage-specific, confined to HGD and 
EAC, respectively. Finally, we applied this knowledge to identify high-risk Barrett’s esophagus in 
a novel non-endoscopic test. In conclusion, mutations in EAC driver genes generally occur 
exceptionally early in disease development with profound implications for diagnostic and 
therapeutic strategies.
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INTRODUCTION
Most epithelial cancers develop gradually from pre-invasive lesions, in some instances after 
an initial metaplastic conversion. Research to characterize the genomic landscape of cancer 
has focused on established invasive disease with the goal of developing biomarkers for 
personalised therapy1. However, it is becoming increasingly clear that extensive genomic 
heterogeneity is present in the majority of advanced cancers2. The most appropriate 
therapeutic targets are therefore those mutations that occur early in the development of 
disease and are thus clonal in the resulting malignancy. The identification of causative 
mutations occurring early in pathogenesis is also pivotal to developing clinically useful 
biomarkers. In this context mutations occurring at disease-stage boundaries, for example, the 
transition from non-dysplastic epithelium to dysplasia, and then to cancer would be most 
informative. The evidence to date on the genetic evolution of cancer from pre-malignant 
lesions suggests that the accumulation of mutations is step-wise3-5. In the most well-studied 
example, the adenoma-dysplasia-colorectal adenocarcinoma progression sequence, it has 
been possible to assign timings for a limited number of candidate genes by comparative 
lesion sequencing3. More recent studies have sought to utilize statistical algorithms to infer 
the life history4,5 of a tumor from single samples.
Esophageal adenocarcinoma (EAC) arises from metaplastic Barrett’s esophagus in the 
context of chronic inflammation secondary to exposure to acid and bile6,7. Barrett’s 
esophagus lends itself well to studies of genetic evolution due to the repeated sampling of 
the mucosa during clinical surveillance prior to therapeutic intervention8. Previous studies of 
EAC and Barrett’s esophagus have generally used candidate gene approaches with the goal 
of identifying clinical biomarkers to complement histological examination, which is an 
approach fraught with difficulties8,9. Data from high-density single nucleotide 
polymorphism (SNP) arrays and exome-sequencing studies are now accumulating with a 
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plethora of mutations identified in many different genes10,11. However, little work has yet 
focused on the precise ordering of these alterations in large cohorts of patients with pre-
malignant disease and associated clinical follow-up data.
Recently Agrawal et al. performed exome sequencing on 11 EAC samples and two samples 
of Barrett’s esophagus adjacent to the cancer. Intriguingly, the majority of mutations were 
found to be present even in apparently normal Barrett’s esophagus 12 similar to the 
observation in colorectal adenocarcinoma. This raises the possibility that prior to the 
progression to malignancy mutations that predict the risk of progression may be detectable 
within cytologically benign tissue. However it is unclear to what extent the same mutations 
may be present in Barrett’s esophagus tissue from patients that have not progressed to 
cancer. This question is important as the majority of patients with Barrett’s esophagus will 
not progress to cancer, and somatic alterations occurring early, prior to dysplasia, are 
unlikely to provide clinically discriminatory biomarkers. Biomarker research in this area is 
critical since the current endoscopic surveillance strategies are increasingly recognized to be 
ineffective13 and therefore novel approaches are required14,15.
The aims of this study were: 1) identify a list of candidate, recurrently-mutated genes in 
EAC; 2) to accurately resolve the stage of disease at which mutation occurs therefore 
providing insight as to the role of these recurrent mutations in cancer progression, and 3) test 
their utility in clinical applications, i.e. using the non-invasive, non-endoscopic, cell 
sampling device, the Cytosponge™.
RESULTS
HIGH MUTATION BURDEN AND UNUSUAL MUTATIONAL SIGNATURE IN EAC
The discovery cohort (22 EACs subject to WGS, Figure 1) reflected the known clinico-
demographic features of the disease: male predominance (M:F, 4.5:1), a mean age of 68 
years (range 53 to 82), and a majority with advanced disease (81.8% (18/22) > stage I). Of 
the 22 cases, 17 (77.3%) had evidence of Barrett’s esophagus in the resection specimen 
(Table 1 and Supplementary Table 1). Patient samples were sequenced to a mean coverage 
of 63- and 67-fold in tumor and normal samples respectively (Supplementary Table 2, 
normal squamous or blood was used as outlined in Supplementary Table 1).
We identified a median of 16,994 somatic SNVs (range: 4,518-56,528) and 994 small indels 
per sample (range 262-3,573). From this final dataset a total of 1,086 coding region 
mutations were subject to verification as part of a larger pipeline bench marking study (see 
online Methods). We used ultra-deep targeted re-sequencing, achieving a median coverage 
of >13,000 fold, and confirmed 1,081 (99.5%) as somatic. Using Sanger sequencing, 23/25 
(92%) indels were verified as real and somatic. As observed by Dulak et al in the 
intervening time since our study commenced11, the most frequent mutation type across the 
discovery cohort was T:A>G:C transversions with a striking enrichment at CTT 
trinucleotides (Supplementary Figure 1). This enrichment for T:A>G:C transversions 
differentiates EAC from other cancers that have been studied by WGS, including breast, 
colorectal and hepatocellular16-18.
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TARGETED AMPLICON RESEQUENCING IN A VALIDATION COHORT OF EACs
To highlight genes most likely to be relevant in the development of EAC in Barrett’s 
esophagus, we sought to determine the degree to which mutated genes identified in our 
discovery cohort (n=22 cases) were representative of the spectrum of mutations in an 
expanded cohort. Hence, a final list of 26 genes that were either mutated significantly above 
the background rate or in pathways of interest were selected (Supplementary Note) and 
tested in a larger cohort (90 additional EACs, Table 1 and Supplementary Table 3), using 
targeted amplicon-resequencing. The findings confirmed and extended those of our 
discovery cohort and previous work from others11,12,19, including the identification of 
recurrent mutations in the SWI/SNF complex, such as ARID1A (Supplementary Figure 2). 
Analysis of ARID1A protein expression loss by immunohistochemistry in a cohort of 298 
additional EACs identified absent or decreased expression in 41% (122/298). This suggests 
alternative mechanisms of down regulation may be present though we did not identify any 
large-scale structural variants within the WGS data from our discovery cohort (data not 
shown).
We next combined the data from both the discovery and validation cohorts and identified 15 
genes that were mutated in four or more samples (Figure 2). These included those previously 
identified as EAC candidate genes, and several novel candidates: MYO18B, SEMA5A and 
ABCB1. Comparison with the recent EAC exome sequencing from Dulak et al confirmed 
that these genes were recurrently mutated in an external data set (Supplementary table 4). 
TP53 was mutated in the majority of cases; however 31% of cases are wild type for TP53. 
Although we do not have enough power to detect mutually-exclusive mutations in our 
cohort, we can detect significantly co-occurring mutations. SEMA5A and ABCB1 mutations 
occurred more commonly in the same tumor than would be expected by chance (Benjamini-
Hochberg-adjusted p-value = 0.0021) although the reason for this association remains 
unclear.
SIMILAR MUTATION FREQUENCY ACROSS DISEASE STAGES
The stage specificity of mutations can be derived from patients at discrete stages of Barrett’s 
esophagus carcinogenesis. Mutations occurring at disease-stage boundaries would be 
candidate biomarkers of malignant progression. In addition, mutations occurring early in the 
development of disease should represent ideal targets for novel therapeutic interventions due 
to their presence in the majority of cells in more advanced lesions due to clonal expansion 
early in the natural history. We therefore sought to identify the mutation status of the 26 
genes in our panel in Barrett’s esophagus samples obtained from a prospective cohort of 
patients undergoing endoscopic surveillance. This included 109 Barrett’s esophagus biopsies 
from 79 patients (Figure 1). We selected 66 never-dysplastic Barrett’s esophagus samples 
from 40 Barrett’s esophagus patients for whom there was no evidence for progression to 
dysplasia or malignancy (median follow-up time 58 months, range 4-132), and 43 Barrett’s 
esophagus biopsy samples (from 39 patients) of histopathologically confirmed high grade 
dysplasia (HGD), the stage just prior to the development of invasive EAC (Table 1). We did 
not include low-grade dysplasia due to the poor agreement on the histopathological grading 
of this lesion20.
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The findings were striking and unexpected. For the never-dysplastic Barrett’s esophagus 
cohort, 21/40 (53%) patients were found to have mutations within their Barrett’s esophagus 
segment (Figure 3a), with several biopsies containing multiple mutations (Supplementary 
Table 5). In total, we identified 29 SNVs and 7 indels within this cohort. Importantly, the 
mutations identified in never-dysplastic Barrett’s esophagus occurred in several genes 
previously identified as drivers in EAC11,19 and other cancers21,22, including SMARCA4, 
ARID1A, and CNTNAP5 (Figure 3b). Of interest, seven of these 29 SNVs were mutations at 
T:A base pairs. Of these, 5/7 (71%) occurred at TT dinucleotide sequences, the mutational 
context identified as highly enriched in the EAC WGS data. Thus, this mutational process 
may well be active at the earliest stages of disease. Of the 43 HGD biopsy samples, 39 
(91%) were found to have mutations in at least one of the genes in our panel with a total of 
67 SNVs and 7 indels. Hence, rather than the frequency of mutation in a given gene 
increasing across disease stages, we observed that for the vast majority of genes the 
mutational frequency was not significantly different between never-dysplastic Barrett’s 
esophagus, HGD and EAC (Fisher’s exact test with Benjamini-Hochberg correction for 
multiple testing, Figure 3b and Supplementary Table 6). For two genes, MYO18B and 
ARID1A we performed amplicon sequencing in an additional 25 NDBE samples and 11 
HGD increasing the cohort to a total of 91 NDBE and 54 HGD, but did not identify any 
significant difference in frequency of mutation between disease stages (Supplementary table 
7). Only TP53 (p<0.0001) and SMAD4 p=0.0061) (Figure 3b and c) exhibited mutational 
frequencies that would distinguish between disease stages and thus identify progression 
towards malignancy. TP53 was found to be recurrently mutated in both HGD (72%) and 
EAC (69%) samples, but only in a single case (2.5%) of never-dysplastic Barrett’s 
esophagus. SMAD4 was mutated at a lower frequency (13%) and intriguingly was only 
found in EAC, the invasive stage of disease.
CLONAL ANALYSIS OF RECURRENT MUTATIONS
Having identified the occurrence of mutations in the earliest stages of disease development 
we next sought to identify whether these mutations were fully-clonal or sub-clonal in our 
original discovery cohort of 22 EACs. For each of the 15 genes mutated in ≥4 samples from 
our expanded cohort we combined our high-depth resequencing of SNVs, copy number 
variant data and LOH analysis to determine the fraction of tumor cells containing the 
mutation (Supplementary Note). If mutation occurs at the earliest stage of disease 
development, prior to the clonal expansion of the malignancy, we would expect that the 
mutation would be present in all cells of the tumor. For 7/15 genes; SMAD4, TP53, ARID1A, 
SMARCA4, TLR4, CDKN2A and PNLIPRP3 this was the case. Mutation in the other 8 genes 
(MYO18B, TRIM58, CNTNAP5, ABCB1, PCDH9, UNC13C and CCDC102B) was not 
always present in the major clone (Supplementary Figure 3), suggesting that mutation of 
these genes may be selected for at multiple stages of tumorigenesis.
APPLICATION OF MUTATIONAL KNOWLEDGE TO A DIAGNOSTIC TEST
The current clinical strategy for patients with Barrett’s esophagus involves regular 
endoscopic examinations to try and identify patients with dysplasia who are at high risk of 
progression to adenocarcinoma. This approach is highly controversial due to the inherent 
difficulties in accurate identification of dysplastic lesions, and recent data suggest that 
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endoscopic surveillance of Barrett’s esophagus is not effective13,23. The difficulties 
involved in endoscopic surveillance for Barrett’s esophagus include sampling bias inherent 
in random biopsies protocols and the subjective and time-consuming histopathological 
diagnosis of dysplasia. We therefore developed a novel approach which has the potential to 
overcome these limitations of Barrett’s esophagus surveillance. The strategy comprises a 
non-endoscopic device called the Cytosponge™ which can be provided to patients in the 
primary care setting. This device collects cells from the entire esophageal mucosa, thus 
avoiding sampling bias and can be combined with objective biomarkers for diagnosis24,25. 
To date our focus has been on a biomarker for diagnosing Barrett’s esophagus, however, 
since most Barrett’s esophagus patients will not progress to EAC, this Barrett’s esophagus 
biomarker needs to be combined with a biomarker (or a panel of biomarkers) to identify the 
high-risk dysplastic patients. From the aforementioned sequencing data, TP53 mutations fit 
the criteria of a good risk stratification candidate marker, since TP53 mutations discriminate 
between patients with and without high grade dysplasia, the key point of therapeutic 
intervention. Though the device samples abnormal tissue, the majority of cells collected are 
from normal gastric glandular tissue at the top of the stomach as well as normal squamous 
areas of the esophagus, and therefore any mutant DNA would theoretically be in the 
minority, requiring a very sensitive assay (Supplementary Figure 4). This situation is 
analogous to the detection of tumor cell-free DNA in blood as a biomarker in advanced 
malignant disease: sensitive assays have been developed to detect extremely low levels of 
mutant DNA against normal background26,27. We therefore took an analogous approach to 
detecting mutations in Cytosponge™ material.
To determine whether mutations within Barrett’s esophagus lesions could be detected in 
material collected from the Cytosponge™, we first tested mutations previously identified in 
endoscopic Barrett’s esophagus biopsies. Four patients with HGD dysplasia had TP53 
mutations and had also swallowed the Cytosponge™ (twice in patient 4). For all four 
patients, the specific TP53 mutations were detected at an allele fraction (proportion of 
variant reads) of between 0.04 and 0.24 (Table 2).
We then tested whether we could detect unknown TP53 mutations within material collected 
using the Cytosponge™ as this would be required for a clinical test. We amplified the 
majority of the coding region of TP53 (1019/1182 bp (86%)) by multiplexed PCR and 
sequenced the amplified DNA by massively-parallel sequencing. TP53 mutations were 
called de novo using TAm-Seq26 on samples from control patients (no Barrett’s esophagus), 
Barrett’s esophagus patients with no dysplasia as well as Barrett’s esophagus patients with 
high grade dysplasia. As we expected, no TP53 mutations were identified in samples from 
control patients or Barrett’s esophagus patients with no dysplasia (Figure 4a), demonstrating 
100% specificity in differentiating between patients with HGD and no dysplasia. In contrast, 
TP53 mutations were identified in 19/22 (86%) HGD patients (details of individual 
mutations can be found in Supplementary table 8). The allele fractions of the TP53 
mutations varied widely (between 0.006 to 0.357) but anything in this range can be called 
successfully and mutations were mostly clustered in the DNA binding domain, as expected 
(Figure 4b).
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DISCUSSION
Barrett’s esophagus is the only known precursor lesion of EAC, co-occurring in >80% of 
cases presenting de novo28, however the majority of Barrett’s esophagus patients will never 
progress to invasive disease29. There is therefore a need for sensitive and specific 
biomarkers that can identify those patients at risk of progression. As long ago as the Nowell 
hypothesis, a stepwise selection of genomic mutations has been assumed necessary for 
cancer development30. Somatic genomic variants should therefore be highly sensitive and 
specific markers of disease stage. By screening for our panel of recurrently-mutated genes in 
a cohort of patients with Barrett’s esophagus who had never developed dysplasia, and a 
cohort of those with HGD, we hoped to identify a step-wise accumulation of mutations 
across these disease stages. Surprisingly we identified numerous mutations occurring in 
never-dysplastic Barrett’s esophagus at detectable allele fractions (>10%). Intriguingly the 
most prevalent gene mutations in EAC were also present at a similar frequency in Barrett’s 
esophagus and HGD samples, including mutations within cancer-associated genes, for 
example ARID1A and SMARCA4, members of the SWI/SNF complex. These data 
demonstrate the complex mutational landscape that may be present even within tissue with a 
very low risk of malignant progression which has an entirely benign histopathological 
appearance. The exact role of these mutations at such an early stage of disease development 
remains unclear. However, it is known that clonal expansions occur frequently in Barrett’s 
esophagus and it is possible that these mutations provide an increase in fitness of a clone 
without leading to disruption of the epithelial architecture or providing the necessary cellular 
characteristics for invasion. A similar observation has been reported in endometrial cancer. 
In the normal population ~35% of women harbour PTEN mutant glands in their endometrial 
tissue yet the lifetime risk of endometrial cancer is ~2.5%31.
Our result has substantial implications for the specificity of tests aiming to use highly 
sensitive detection of mutations for the early diagnosis of malignancy32. Biomarkers 
predicting individuals at risk for cancer need to have substantial predictive power to 
distinguish between those who will and will not develop cancer. In our study almost all 
recurrently mutated genes in EAC, including ABCB1, CNTNAP5, MYO18B amongst others, 
are ruled out for use as surveillance tools for progression risk. Only mutation in TP53 and 
SMAD4 accurately defined the boundaries of disease states. The fact that mutation of 
SMAD4 was only found in EAC provides a clear genetic distinction between EAC and 
HGD. However, the low frequency of SMAD4 mutation (13%) makes it a sub-optimal 
candidate for biomarker development. Furthermore, HGD, rather than EAC, is now the ideal 
point of clinical intervention due to the advent of endoscopic therapy. We therefore focused 
on TP53 for the proof-of-principle Cytosponge™ study. Sequencing technologies are now 
being introduced to routine clinical use, and genes of interest can be sequenced rapidly and 
with exquisite sensitivity, providing a quantitative read-out26.
We detected mutations in 86% of HGD Cytosponge™ samples using a simple, clinically 
applicable test. To improve the sensitivity of any early detection programme, it will also be 
key to identify the genetic or epigenetic changes that drive HGD and EAC in the minority of 
patients without a detectable TP53 mutation. In addition, since genetic diversity has been 
shown to predict progression to Barrett’s esophagus it may be possible to perform somatic 
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mutation testing looking at both presence and relative proportions of mutations in a panel of 
genes, to identify patients with high-risk disease33.
In conclusion, never-dysplastic Barrett’s esophagus harbours frequent mutations affecting 
recurrently-mutated genes in EAC. Given the low rate of progression to malignant disease in 
never-dysplastic Barrett’s esophagus, the role of these mutations on the road to malignancy 
is unclear. It is generally accepted that the mutations observed in a tumor are accrued in a 
linear progression with each step bringing the clone closer to the invasive endpoint. Our 
observation of mutations in almost all of the recurrently-mutated genes in the tissue of 
patients who have not gone on to develop malignancy argues against a major role of these 
mutations in the progression towards cancer. Though their recurrent nature suggests a role in 
clonal expansion at the pre-malignant stage they do not seem to provide any long term 
increase in the likelihood of malignant progression. It is likely that additional sequencing 
cohorts with greater sample numbers and differing demographics will identify further 
recurrently-mutated genes in EAC, and these too will need careful analysis to determine the 
disease stage at which they occur.
From a clinical perspective, because the vast majority of recurrently-mutated genes in EAC 
do not differentiate between the pre-malignant and malignant stages of disease, they 
therefore cannot be applied in a simple binary test, i.e. mutant or non-mutant, as biomarkers 
of malignant progression. The Cytosponge™ provides a representative sample of the entire 
esophageal mucosa and coupled with high-throughput sequencing is capable of sensitive and 
objective detection of HGD. This approach could be readily adapted as our understanding of 
the genetic basis for this disease evolves. Furthermore, our systematic molecular approach to 
identify key mutations involved in the steps distinguishing pre-inasive from invasive disease 
has applicability to other epithelial cancers amenable to early detection.
ONLINE METHODS
Sample Collection, Pathology Review and Extraction
The study was approved by the Institutional Ethics Committees (REC Ns 07/H0305/52 and 
10/H0305/1) and all patients gave individual informed consent. For the discovery cohort, 
esophageal adenocarcinoma (EAC) patients were recruited prospectively and samples were 
obtained either from surgical resection or endoscopic ultrasound (EUS). This was an 
exploratory pilot with no pre-specified effect size. Blood or normal squamous esophageal 
samples, distant at least 5cm from the tumor, were used as germline reference. All tissue 
samples were snap-frozen in liquid nitrogen immediately after collection and stored at 
−80°C. Prior to DNA extraction, one section was cut from each oesophageal tissue sample 
and H&E staining was performed. Cancer samples were deemed suitable for DNA 
extraction only after consensus review by two expert pathologists had confirmed tumor 
cellularity ≥70%. Where blood was not available the same review process was applied to the 
normal esophageal samples to ensure that only squamous epithelium was present. For the 
Discovery cohort 127 cases were screened from two centers (Cambridge and Southampton). 
63 cases had 70% cellularity required to meet ICGC criteria and of these 22 tumor:normal 
pairs had sufficient quality and quantity of DNA extracted (total yield ≥ 5μg), and were 
submitted for whole genome sequencing. From the remaining 105 cases available, 90 had 
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>50% cellularity and all of these had sufficient DNA for the amplicon sequencing. For all 
cases in the discovery and validation cohort there was a 260/280 ratio 1.8-2.1. For the pre-
invasive disease cohort we screened our entire 10 year prospective Barrett’s cohort of >500 
patients and selected cases in which there was frozen material available and for which 
review of the frozen section revealed a homogeneous grade of dysplasia following expert 
histopathological review. The Cytosponge™ samples were all those available as part of an 
interim analysis from an ongoing prospective case-control study (BEST2).
DNA was extracted from frozen esophageal tissue using the DNeasy kit (Qiagen) and from 
blood samples using the Nucleon™ Genomic Extraction kit (Gen-Probe) according to the 
manufacturer’s instructions. For validation DNA was extracted using the AllPrepDNA/RNA 
Mini Kit (Qiagen) according to the manufacturer’s instructions.
Whole Genome Sequencing
A single library was created for each sample, and 100bp paired-end sequencing was 
performed under contract by Illumina to a typical depth of at least 50x, with 94% of the 
known genome being sequenced to at least 8x coverage while achieving a PHRED quality of 
at least 30 for at least 80% of mapping bases. Typically, 5 lanes of a HiSeq-2000 (Illumina) 
flow cell achieved this, but samples were not multiplexed, so some exceeded these minimum 
standards by a large margin. Filtered read sequences were mapped to the human reference 
genome (GRCh37) using Burrows-Wheeler Alignment (BWA)34, and duplicates marked 
using Picard (http://picard.sourceforge.net). As part of an extensive quality assurance 
process, QC metrics and alignment statistics were computed on a per lane basis. Aggregated 
QC for each discovery cohort sample is given in Supplementary Table 9. Details of any tiles 
within flow cells that were removed post-QC are shown in Supplementary Table 10.
The FastQCpackage (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was used 
to assess the quality score distribution of the sequencing reads, and enabled the 
identification of three lanes of sequencing that required trimming due to a drop in quality in 
the later cycles of sequencing (see details in Supplementary Table 11).
WGS Mutation Calling
Somatic single nucleotide variants (SNVs) were predicted using SomaticSniper V1.0.235 run 
with the following command: somaticsniper -q 1 -Q 15 -F vcf -J -r 0.001000 -T 0.850000 -N 
2 -s 0.01 -f The output from SomaticSniper was then filtered using the following criteria 
derived from comparison of heuristic filters applied to SomaticSniper and VarScan 236 and 
implemented using scripts provided in Koboldt et al36 and custom scripts (homopolymer 
filter). The filtering criteria were; 1) germline and tumor sample coverage ≥10, 2) average 
variant position in read between positions 10 and 90, 3) percentage of supporting reads from 
each strand ≥1% and ≤99%, 4) total number of supporting reads ≥4, 5) average distance of 
variant base from effective 3′ end of supporting reads ≥20 bp, 6) average mapping quality 
difference between reference and variant supporting reads <30, 7) average difference in 
length of trimmed sequences between reference and variant reads <25bp, 8) mismatch 
quality sum difference <100 between reference and variant reads, 9) adjacent homopolymer 
<5bp away, and 10) nearest indel ≥ 40bp away. In addition, all variants were compared to 
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dbSNP129 and removed if overlapping with predicted germline SNPs. A median of 99.7% 
of the mappable genome was covered to at least 10-fold coverage in the tumor and matched 
germline sample and so was defined as callable (Supplementary Table 12).
Candidate somatic indels were taken as the consensus between SAMtools37 and Pindel38, 
filtered to exclude those indels present in the matched normal genome of any of the 22 
samples (including non-consensus indel calls). Indels falling within coding regions and 
splice sites were manually inspected to generate a final list of calls. Variants were annotated 
with sequence ontology terms to describe consequence and position relative to Ensembl 
gene annotations. SNVs and indels were also annotated with matching or nearest features in 
UniSNP.
Verification of indel variants by PCR
A total of 25 coding indels, confirmed by manual review, were randomly selected for 
verification. Primers (sequences available on request) were designed to amplify the 
predicted variant location. PCR was performed on both the tumor and normal DNA and the 
resulting products were Sanger sequenced. All traces were visualized using Chromas lite 
2.01 and were manually reviewed for presence of the variant. An indel was considered 
somatic if it was present only in the tumor trace.
Verification of single nucleotide variants by targeted re-sequencing
As part of a larger benchmarking exercise of our SNV calling pipeline we selected 2007 
SNVs to be verified. These SNVs included those that had failed filters and those that had 
been predicted using the Illumina pipeline, ELAND alignment plus STRELKA. The 
complete analysis of these data is ongoing with the overall aim of optimizing the sensitivity 
of our SNV calling pipeline. Following a preliminary analysis and comparison to the ICGC 
benchmarking exercise we chose to increase the stringency of our filters for this pilot dataset 
(detailed above). The verification data in this manuscript is for only those SNVs passing 
these additional filters. Putative non-synonymous SNVs (1330 in total) underwent ultra-
high-depth targeted sequencing. For eight samples all non-synonymous variants were sent 
for verification. In the remaining 14 cases, the selected SNVs were restricted to non-
synonymous variants in genes mutated in more than one sample. Amplicons were generated, 
indexed and pooled, and libraries constructed as per Shah et al39. Samples were pooled 
separately and a single lane of HiSeq-2000 data was generated for each, leading to a typical 
depth of coverage of 13,855 (IQR:3,408 to 39,059 for the amplicons). For 1086 of these 
≥50-fold coverage was generated for both tumor and normal. An SNV was confirmed as 
somatic if the variant allele frequency was ≤ 1% in the matched normal and ≥ 2% in the 
tumor, and 1081 SNVs met these criteria giving a verification rate of 1081/1086 (99.5%).
Mutation validation in independent samples
Mutation validation was performed in a cohort of 90 additional EACs and 109 Barrett’s 
esophagus biopsies, including 43 Barrett’s esophagus biopsies with histopathologically 
confirmed HGD and 66 with no dysplasia. The Access Array microfluidics PCR platform 
(Fluidigm) together with high-throughput sequencing (Illumina) was used for the targeted 
re-sequencing.
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Amplicons with a median size of 180bp (range 100-200bp) were designed using Fluidigm 
in-house software (primers available on request)26. After two iterations of primer design, 
one gene remained uncovered by suitable amplicons (DIRC3) and this was removed from 
further analysis. Hence, in total 26 genes were selected (Supplementary Table 13 and 14). 
All primers were synthesised with universal sequences (termed CS1 and CS2) appended at 
the 5′-end.
Target amplification and sample barcoding was performed using the manufacturer’s 
standard multiplex protocol (Fluidigm, Access Array User Guide). Primers were combined 
into multiplex pools ranging from 1 to 12 primer pairs. The Access Array system was used 
to combine PCR reagents (FastStart High Fidelity PCR System, Roche) with 47 DNA 
samples (50ng) plus a single negative control and 48 sets of multiplexed primers into 2,304 
unique 35nL PCR reactions. Thermal cycling was then applied to amplify all selected targets 
by PCR. Post-PCR, a harvesting reagent was used to collect the amplified products of the 
48-multiplex reactions, per sample, through the sample inlets, for subsequent sequencing. 
Illumina sequencing adaptors and a 10bp sample specific barcode were attached through an 
additional 15 cycles of PCR. After the PCR products were barcoded, the PCR products from 
a small number of samples, as well as the water controls, were analyzed using the Agilent 
2100 BioAnalyzer to ensure the expected amplicon size was obtained and that there was no 
contamination across the PCR reactions. They were then pooled together and purified using 
AMPure XP beads using a bead to amplicon ratio of 1.8:1.0. The library was quantified 
using the Agilent BioAnalyzer and subjected to Illumina cluster generation. One-hundred to 
150bp paired-end sequencing was performed on a HiSeq 2000 or MiSeq with a 10-base 
indexing (barcode) read, using custom sequencing primers targeted to the CS1 and CS2 tags 
for both read1, read 2 (index read) and read 3, according to manufacturer’s 
recommendations.
Methods used for analysis of targeted sequencing data generated using TAm-Seq have been 
reported previously26. Reads were de-multiplexed using a known list of barcodes allowing 
zero mismatches. Each set of reads was aligned independently to the hg19 reference genome 
using BWA in the paired-end mode34. Using expected genomic positions, each set of 
aligned reads was separated further into its constituent amplicons. A pileup was generated 
for each amplicon using SAMtools v1.1737. Using a base quality and a mapping quality cut-
off of 30, observed frequencies of non-reference alleles for every sequenced locus across all 
amplicons and barcodes were calculated. For each locus and base, the distribution of non-
reference background allele frequencies/reads was modeled and the probability of obtaining 
the observed frequency/number of reads (or greater) was calculated. Putative substitutions 
were identified based on a probability cut-off (confidence margin) of 0.9995. Known SNPs 
obtained from the 1000 Genomes project, dbSNP version 135 and regions covering 
amplification primers were discarded. Any substitutions observed at >5% allele frequency in 
more than half of the sequenced samples were discarded. Small insertions and deletions of 
sequence were predicted using GATK (this tool was preferred to samtools/pindel for the 
higher depth of sequencing). All remaining putative mutations were annotated with 
sequence ontology terms to describe consequence and position relative to Ensembl gene 
annotations. In the final list, all nonsense or missense exonic mutations and splicing 
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mutations with an allele frequency of 10% or greater at loci covered at least 100-fold were 
retained. Three genes were removed at this stage due to poor sequence coverage in all 
samples, TLR1, TLR7 and TLR9, leaving a total of 23 genes for further analysis 
(Supplementary Table 14).
In order to verify the called mutations, all nonsynonymous mutations identified from the 
Fluidigm Access Array sequencing were re-amplified using the CS1-/CS2-tagged primer 
pair targeting the region and DNA from the original sample. Where available, DNA from a 
matched normal sample (blood, duodenum or normal squamous epithelium) was also 
amplified using the identical, tagged primer pair. Amplification was performed in 5 μl 
reactions (0.1 Phusion® High-Fidelity DNA Polymerase (New England BioLabs), 1x 
Phusion Buffer, 4.5 mM MgCl2, 5% DMSO, 0.2 mM dNTPs, 1 μM forward and reverse 
primer, 25 ng genomic DNA. The PCR cycling conditions were as follows; 50°C for 2 
minutes, 70°C for 20 minutes, 95°C for 10 minutes followed by 10 cycles of 95°C for 15 
seconds, 60°C for 30 seconds and 72°C for 1 minute, followed by 2 cycles of 95°C for 15 
seconds, 80°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute, followed by 8 
cycles of 95°C for 15 seconds, 60°C for 30 seconds and 72°C for 1 minute followed by 2 
cycles of 95°C for 15 seconds, 80°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 
minute, and 8 cycles of 95°C for 15 seconds, 60°C for 30 seconds and 72°C for 1 minute 
followed by 5 cycles of 95°C for 15 seconds, 80°C for 30 seconds, 60°C for 30 seconds and 
72°C 1 minute. Following amplification, 2μl of each PCR reaction were collected and 
pooled in batches of 12 reactions such that only unique amplicons were contained within 
each pool. Thereafter, 5μl of the pooled reaction mix was added to 2μl of ExoSAP-IT® 
(Affymetrix). The samples were incubated at 37°C for 15 minutes followed by 80°C for 15 
minute. The resulting product was diluted 1:100 in sterile water and Illumina sequencing 
adaptors and a 10bp barcode was attached to each pool using an additional 15 cycles of PCR 
(0.1 unit Phusion® High-Fidelity DNA Polymerase (New England BioLabs), 1x Phusion 
Buffer, 4.5mM MgCl2, 5% DMSO, 0.2mMdNTPs, 1 μM forward and reverse barcoding 
primers, 1μl ExoSAP-IT®-treated PCR product (1:100 dilution). Cycling conditions were as 
follows: heat activation at 95°C for 2 minutes, followed by 15 cycles of 95°C for 15 
seconds, 60°C for 30 seconds and 72°C for 1 minute, followed by a final elongation step of 
72°C for 3 minutes.
As previously, PCR products following barcoding were first analyzed using an Agilent 2100 
BioAnalyzer to ensure the expected amplicon size was obtained. They were then pooled 
together and purified using AMPure XP beads using a bead to amplicon ratio of 1.8 to 1.0. 
The library was quantified using the KAPA-Library Quantification Kit (KAPA Biosystems) 
on a Lightcycler® 480 (Roche), diluted to 2nM and subjected to Illumina cluster generation 
and sequencing on the Illumina MiSeq (150bp paired-end). Reads were de-multiplexed 
using a known list of barcodes allowing zero mismatches. Each set of reads was aligned 
independently to the hg19 reference genome using BWA in the paired-end mode34. 
Samtoolsmpileupv1.1737 was used to generate counts for each nucleotide at the position of 
the putative somatic mutation. Samples with a mutant allele frequency ≥3% and a depth of 
coverage ≥ 50 were considered as verified mutations. In addition, mutant allele frequency in 
the matched normal was required to be <1%. We additionally removed all mutations from 
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those samples without a matched normal that were confirmed as germline in the cohort of 
samples with sequenced matched normal.
Processing of the capsule sponge specimens
Cytosponge™ capsules were swallowed by patients and then placed directly into 
preservative solution at 4°C until processed further. The samples were vortexed extensively 
and shaken vigorously to remove any cells from the sponge material. The preservative liquid 
containing the cells was centrifuged at 1000 RPM for 5 minutes to pellet the cells. The 
resulting pellet was re-suspended in 500 μL of plasma and thrombin (Diagnostic reagents, 
Oxford, UK) was then added in 10 μL increments until a clot formed. The clot was then 
placed in formalin for 24h prior to processing into a paraffin block. Eight times ten 
micrometer sections were cut and placed in a tube for DNA extraction.
DNA extraction from the Cytosponge samples
Genomic DNA was extracted from 8 × 10μm sections of the processed Cytosponge™ FFPE 
clot using Deparaffinization Buffer (Qiagen) and the QIAamp FFPE DNA Tissue Kit 
(Qiagen). The protocol was followed as described by the manufacturer with the exception 
that samples were incubated at 56°C for 24 hours instead of the described 1 hour, and 10 μl 
of extra Proteinase K was added to the samples roughly half way through the 24 hour 
incubation. After extraction, DNA was quantified using the Qubit™ dsDNA HS Assay Kits 
(Invitrogen)
Sequencing for TP53 mutations
A multiplex TP53 PCR assay was used to sequence the coding region of the TP53 gene. The 
multiplex consisted of 14 primer pairs26 and these 14 primer pairs were divided into two 
different pools. The sequences of each of the primers, the genomic region that they amplify 
(co-ordinates are correct for the hg19 version of the human genome) as well as which pool 
they were part of are described in Supplementary Tables 15 and 16.
All p53 multiplex PCRs were performed in duplicate using Q5 Hot start High-Fidelity 2X 
Master Mix (New England Biolabs). The coding region of the TP53 gene was first amplified 
using a PCR mix consisting of: 1 × Q5 master mix, 5% DMSO, final concentration of 50 
nM of each primer pair and up to 70 ng of FFPE DNA extracted from Cytosponge samples. 
The cycling conditions for the PCR were: Initial denaturation at 95°C for 30 seconds 
followed by 30 cycles of 95°C for 10 seconds, 60°C for 10 seconds and 72°C for 15 
seconds. A final extension at 72°C for 2 minutes was also included to ensure elongation of 
all PCR products.
After the first round of PCR, 2.5 ul of Pool 1 and 2.5ul of Pool 2 were pooled together. Two 
microlitres of IllustraExostar, 1-step (GE Healthcare UK Ltd) was added to the 5 ul of 
pooled PCR products and the Exostar reaction was performed (15 minutes at 37°C followed 
by 15 minutes at 80°C) to degrade the primers from the first reaction. One microlitre of the 
pooled, Exostar-treated products was then added to the barcode PCR in order to add a 
unique barcode as well as add the sequencing primers onto the PCR products. The barcodes 
used for this second PCR were taken from Forshew et al26 and the core sequence of the 
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barcode primers can be found in Table 17. The Fluidigm barcode primers were used as they 
contain a sequence that binds to the CS1 and CS2 sequences present in the first p53 primers 
as well as the Illumina adapters. The barcode PCR mix consisted of 1 × Q5 master mix, 5% 
DMSO, final concentration of 400 nM of each barcode primer pair and 1 ul of undiluted, 
Exostar-treated DNA. The cycling conditions for the PCR were: Initial denaturation at 98°C 
for 30 seconds followed by 14 cycles of 98°C for 10 seconds, 60°C for 10 seconds and 72°C 
for 30 seconds. A final extension at 72°C for 2 minutes was also included to ensure 
elongation of all PCR products.
TAm-seq SNV and indel calling for detecting TP53 mutations on Cytosponge™ samples
Indels were called by selecting outliers from locus-specific distributions of background 
mutation rates. Candidate insertions and deletions in each sample were compared with 
insertion and deletion rates at the same locus in samples from every other patient, and scored 
by means of z-scores. Indels with a z-score greater than or equal to 10, at least 200x 
coverage and at least 5 supporting reads were retained.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Flow chart illustrating the study outline
The number of samples used at each stage is given. The methodology used for each study 
phase is shown on the left hand side. EAC, Esophageal adenocarcinoma, BE, Barrett’s 
esophagus, HGD, high grade dysplasia.
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Figure 2. Mutation in esophageal adenocarcinoma
The bar graph on the top indicates the percentage of samples with aberrations for a given 
gene. The number in bold denotes the total number of mutations for each gene. Genes with 
four or more mutations in our EAC discovery and validation cohort (combined total of 112 
patients) were included. The proportion of missense, nonsense/splice and indel mutations are 
shown. The matrix below shows the number of samples with mutations in both genes for 
each possible pairing of genes. The red highlighted box indicates significantly co-occurring 
mutations (Significance was assessed empirically from 100,000 permutations. False 
discovery rate was controlled using the Benjamini-Hochberg procedure.).
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Figure 3. TP53 and SMAD4 mutations accurately define the boundaries in the progression 
towards cancer whilst other mutations appear to occur independent of disease stage
A. Bar graph showing the number of never-dysplastic Barrett’s esophagus patients (NDBE) 
(n=40), Barrett’s esophagus patients with high grade dysplasia (HGD) (n=39) and EAC 
patients (n=112) with at least one mutation in our panel consisting of 26 genes. B. 
Percentage of never-dysplastic Barrett’s esophagus, Barrett’s esophagus with HGD and 
EAC samples with mutations in recurrently-mutated genes (mutated in ≥4 samples) 
identified in the EAC discovery cohort and EAC Validation cohort. TP53 and SMAD4 are 
the only genes for which mutations separate the boundaries between never-dysplastic and 
dysplastic Barrett’s esophagus (TP53) or cancer (SMAD4) (two-tailed Fisher’s exact test 
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with Benjamini-Hochberg correction for multiple testing, * p<0.05). C. Proposed model for 
the boundary-defining mutations in Barrett’s esophagus carcinogenesis. The hashed box 
depicts multiple other mutations which may occur and provide selective advantage at any 
stage of disease.
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Figure 4. TP53 mutations can be used to diagnose Barrett’s esophagus with prevalent high-grade 
dysplasia on the Cytosponge™
A. The allele fraction of TP53 mutations identified in Cytosponge™ samples is shown for 
the three patients groups: no Barrett’s esophagus (n=23), Barrett’s esophagus with no 
dysplasia (n=44) and Barrett’s esophagus with high grade dysplasia (HGD) (n=22). B. The 
positions of the TP53 mutations identified on the Cytosponge™ samples are shown above 
the gene diagram compared with those found in the EAC and Barrett’s esophagus HGD 
biopsy cohorts. The dotted line on the gene outline denotes the two small areas not covered 
by the multiplex PCR assay (amino acids 1-27 and 361-393). TA, transcription activation 
domain; OD, oligomerization domain.
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Table 1
Demographics of the patient cohorts
EAC cohorts Barrett’s esophagus cohorts TP53 analysis on Cytosponge™
Discovery Validation Never-dysplastic
Barrett’s esophagus
Barrett’s
esophagus 
with HGD
No 
Barrett’s
esophagus 
Controls
Never-dysplastic
Barrett’s esophagus
Barrett’s
esophagus 
with HGD
Number 22 90 40 39 23 44 22
Age (years) 68 (53-82) 66 (32-83) 63 (32-81) 71 (50-87) 53 (28-74) 61 (41-85) 66 (41-82)
Sex (M:F) 5:1 5 : 1 2 : 1 12:1 1 : 2 4 : 1 10 : 1
Stage (%) I 4 (18.2) 14 (15.6)
II 6 (27.3) 14 (15.6)
III 11 (50.0) 49 (54.4)
IV 1 (4.5) 4 (4.4)
n/a 0 (0.0) 9(10.0)
Barrett’s 
esophagus 
length (cm)
4.8 (1-9) 8.6 (2-16) 5.8 (1-12) 8.5 (4-16)
Follow up 
from EAC 
diagnosis 
(months)
28.5 (5-63) 18 (1-134)
Total 
Barrett’s 
esophagus 
surveillance 
(months)
58 (4-132) 1 (0-45) 56 (0-175) 24 (0-180)
*
Data shown reflect mean (range) for age and Barrett’s esophagus length, number (percentage) for stage and median (range) for follow up from 
EAC diagnosis and total Barrett’s esophagus surveillance. Sex ratio rounded to the nearest whole number.
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Table 2
Allele fractions for known TP53 mutations, previously identified by sequencing TP53 on 
diagnostic biopsies
For these four patients the mutation can also be detected in material collected using the Cytosponge™. Patient 
4 swallowed the Cytosponge™ on two different occasions, 8 months apart, and the data for both 
Cytosponge™ samples is shown. N/A = Not applicable as no sample was taken, AF= allele fraction.
AF on Biopsy AF on Cytosponge™
Patient Mutation #1 #2 #1 #2
HGD_01 Chr17: 7574003 G>A 0.35 N/A 0.04 N/A
HGD_40 Chr17: 7577538 C>T 0.23 0.52 0.10 N/A
HGD_03 Chr17: 7578406 C>T 0.51 0.72 0.06 N/A
HGD_04 Chr17: 7577551 C>T 0.19 N/A 0.14 0.24
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